# Novel Yeast Cell Platform Promises to Expedite the Development of Immunotherapies

Researchers have developed a technological platform that leverages yeast cells to test and understand new cancer treatments under development. The use of this platform promises to significantly reduce the costs and time needed in the drug development process.

 The use of immunotherapy to treat cancers is enjoying plenty of scientific attention, with many companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) exploring cutting-edge approaches…

 Read More>>

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/novel-yeast-cell-platform-promises-to-expedite-the-development-of-immunotherapies/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/yeast-cell-platform-accelerates-cancer-immunotherapy-development/2ea805749e034d8146504e488c4e3ed1) 


Pickup - [https://curatedhealthnews.substack.com](https://curatedhealthnews.substack.com/p/2ea805749e034d8146504e488c4e3ed1)

Pickup - [https://curatedtechnologynews.substack.com](https://curatedtechnologynews.substack.com/p/2ea805749e034d8146504e488c4e3ed1)
 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/262/5/yawnpsIb.webp)